胃癌CIK细胞治疗的研究现状及进展

PDF(572 KB)

武警医学 ›› 2013, Vol. 24 ›› Issue (6) : 526-528.

综述

胃癌CIK细胞治疗的研究现状及进展

舒心^¹,李幸^²综述汪治宇^²审校

作者信息 +

文章历史 +

摘要

近年来,随着生物技术的迅猛发展,生物治疗在提高手术、放化疗疗效以及延长患者生存期、改善生活质量等方面已经受到越来越多的关注^[1]。由细胞因子诱导的杀伤细胞(cytokine-inducedkillercells,CIK)作为一类新型的抗肿瘤效应细胞,可直接杀伤肿瘤细胞,并可调节和增强机体的免疫功能,是继淋巴因子激活的杀伤细胞(LAK)、细胞毒T淋巴细胞(CTL)、肿瘤浸润淋巴细胞(TIL)后出现的一类更为有效的杀瘤效应细胞^[2]。目前,CIK细胞已应用于多种肿瘤的治疗^[1,2],并在胃癌治疗中积累了一定经验,笔者就CIK细胞的生物学特征、抗肿瘤机制及在胃癌临床治疗上的应用及进展做一综述。

关键词

胃癌 / CIK细胞 / 应用

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用

舒心,李幸综述汪治宇审校. 胃癌CIK细胞治疗的研究现状及进展[J]. 武警医学. 2013, 24(6): 526-528

中图分类号： R735.2

参考文献

[1] Jiang J, Shen Y, Wu C, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J]. World J Gastroenterol 2010 ,16(48): 6155-6162.

[2] Wu C, Jiang J, Shi L,et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer[J].Anticancer Res, 2008,28: 3997-4002.

[3] Hoffman D M,Gitlitz B J,Belldegrun A,et al.Adoptive cellular therapy[J].Semin Oncol,2000,27(2):221-233.

[4] Yeon Jin Kim, Jaeseung Lim, Jong Soon Kang,et al.Adoptive Immunotherapy of Human Gastric Cancer with Ex Vivo Expanded T Cells[J].Arch Pharm Res,2010, 33(11):1789-1795.

[5] Takayama T, Sekine T, Makuuchi M,et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet,2000,356,802-807.

[6] Schmidt-Wolf I G,Lefterova P,Mehta B A,et al.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells[J].Exp Hematol,1993,21:1673-1679.

[7] Schrmitz M,Zhao S,Deuse Y,et al.Tumorcidal potential of native blood dendritic cells:direct tumor cell killing and activation of NK cell-mediated cytotoxicity[J].J Immunol,2005,174(7):4127-4134.

[8] Bela A Mehta,Schmidt-Wolf IGH,Weissman I L,et al.Two pathways of exocytosis of cytoplasmic granule cotents and target cell killing by cytokine-iuduced CD3+CD56+killer cells[J].Blood,1995,86:3493-3499.

[9] Brinkmann O A, Bruns F, Gosheger G, et al. Treatment of bone metastases and local recurrence from renal cell carcinoma with immuno chemotherapy and radiation[J]. World J Urol,2005,23(3):185-190.

[10] Verneris M R, Kornacker M, Mailander V, et al. Resistance ofex vi-vo expanded CD3+ CD56+T cells to Fas-mediated apoptosis[ J]. Cancer Immunol Immunother, 2000, 49 (6):335-345.

[11] 孙抒,李雪梅,王建光,等.CIK细胞对MGC-803胃癌细胞株抗增殖及诱导凋亡作用的研究[J].中国免疫学杂志,2004,20(12):831-837.

[12] Parkin D M,Bray F,Ferlay J,et al.Global cancer statistics,2002[J]. CA Cancer J Clin,2005,55(2):74-108.

[13] Chen L, Tian H, Chen J, et al.Surgical management of gastric stump cancer: a report of 37cases[J]. J Zhejiang Univ Sci B, 2005,6:38-42.

[14] Lin W L, Li D G, Chen Q, et al. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma[J].World J Gastroenterol, 2004,10: 2911-2915.

[15] Schmidt-Wolf IGH, Negrin R S, Kiem H, et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity [J]. J Exp Med,1991,174:139-149.

[16] Yamaguchi K, Shimamura T, Hyodo I, et al.Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer[J]. Br J Cancer,2006,94:1803-1808.

[17] Margolin K A, Negrin R S, Wong K K,et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy[J]. Immunol Rev,1997,157: 231-240.

[18] 樊永丽,赵华,于津浦,等. 胃癌患者术后化疗联合CIK免疫治疗的临床疗效[J].中国肿瘤生物治疗杂志,2012,19(2):168-174.

[19] Kim Y J,Lim J,Kang J S,et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells [J].Arch Pharm Res,2010,33( 11) : 1789-1795.

[20] 杨光,王彬,何志杰,等.自体CIK细胞治疗晚期恶性肿瘤的临床研究[J].南京医科大学学报﹙自然科学版﹚,2009,29(12):1744-1747.

[21] 蒋敬庭,吴昌平,Ning Xu,等.CIK细胞治疗老年人中晚期胃癌的副反应分析[J].肿瘤,2006,26(10):950-952.

[22] Brinkmann O A,Bruns F,Gosheger G,et al.Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation[J].World J Urol,2005,23(3):185-190.

[23] Jiang J, Xu N, Wu C, et al.Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells[J]. AnticancerRes, 2006, 26: 2237-2242.

[24] 张彤,任国平,张蕊.紫杉醇、奥沙利铂、氟尿嘧啶方案联合自体CIK细胞输注治疗Ⅳ期胃癌的疗效与安全性研究[J].中国临床实践,2012,15(7):2418-2410.

[25] Thome S H,Negrin R S,Contag C H.Synergistic antitumor effects of immune cell—viral biotherapy[J].Science,2006,3(1l):17802-17841.

[26] Liu K,Caldwell S A,Greenetlch K M,et al.CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape[J]. J Immunol,2006,176(6):3374-3382.

[27] Ramakrishnan R, As sudaniD, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility toCTL-mediated killing during cancer immunotherapy in mice [ J]. J Clin Invest, 2010,120(4):1111-1124.

[28] 李辉,毛伟征,安岗,等.细胞因子诱导杀伤细胞杀伤胃癌的特异性与非特异性研究[J].中华实验外科杂志,2012,27(4):428-430.

[29] Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy[J]. Oncologist, 2002, 7 Suppl 4: 2-8.

[30] 张林,侯艳红,段云卉.EGFR单抗联合CIK细胞治疗胃癌的实验研究[J].胃肠病学,2010,15(11):657-660.